212. Long-Term 52-Week Results of Palace 3, A Phase 3, Randomized, Controlled Trial of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis and Current Skin Involvement
Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), C. Birbara(University of Massachusetts Chan Medical School), Randall M. Stevens, Francisco J. Blanco(Complexo Hospitalario Universitario A Coruña), Jeffrey Crowley, ChiaChi Hu
Cited by 29
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis
|Annals of the Rheumatic Diseases|2013|668